Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 80,462 | 111,295 | 112,095 | 91,386 | 93,986 |
| Marketable Securities | 28,842 | 30,306 | 9,711 | 36,994 | 64,050 |
| Receivables | 88,757 | 55,412 | 33,082 | 19,703 | 19,649 |
| Inventories | 24,589 | 20,921 | 16,464 | 8,341 | 7,128 |
| TOTAL | $235,426 | $237,464 | $186,024 | $168,546 | $196,868 |
| Non-Current Assets | |||||
| PPE Net | 597 | 616 | 637 | 695 | 688 |
| Investments And Advances | 0 | 0 | 0 | 380 | 4,632 |
| Other Non-Current Assets | 16,567 | 15,610 | 13,794 | 15,425 | 6,529 |
| TOTAL | $17,164 | $16,226 | $14,431 | $16,500 | $11,849 |
| Total Assets | $252,590 | $253,690 | $200,455 | $185,046 | $208,717 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 39,945 | 35,346 | 27,717 | 26,173 | 30,962 |
| Accrued Expenses | 12,253 | 9,837 | 13,516 | 11,114 | 11,646 |
| Other current liabilities | 7,622 | 5,452 | 3,430 | 4,957 | 4,940 |
| TOTAL | $61,915 | $50,635 | $46,418 | $42,244 | $47,548 |
| Non-Current Liabilities | |||||
| Long Term Debt | 188,734 | 189,530 | 122,210 | 122,111 | 122,508 |
| Other Non-Current Liabilities | 131,398 | 137,778 | 133,826 | 136,099 | 132,037 |
| TOTAL | $323,071 | $327,308 | $259,511 | $258,210 | $254,545 |
| Total Liabilities | $384,986 | $377,943 | $305,929 | $300,454 | $302,093 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 48,722 | 48,682 | 46,809 | 46,264 |
| Common Shares | 135 | 134 | 133 | 128 | 126 |
| Retained earnings | -997,641 | -983,290 | -959,716 | -933,352 | -900,005 |
| Other shareholders' equity | -2 | 8 | 19 | 23 | 6 |
| TOTAL | $-132,396 | $-124,253 | $-105,474 | $-115,408 | $-93,376 |
| Total Liabilities And Equity | $252,590 | $253,690 | $200,455 | $185,046 | $208,717 |